Top

Current Dermatology Reports

Published in:

01-12-2018 | Immunology (D Lee, Section Editor)

Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis

Authors: Houmin Li, Delphine J. Lee, Meiling Yuen

Published in: Current Dermatology Reports | Issue 4/2018

Abstract

Purpose of Review

Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life. This review aims to summarize the advances in immune pathways and pathogenesis of AD.

Recent Findings

We review and summarize the current literature characterizing immune pathways and pathogenesis of AD. The complex interplay among skin barrier deficiency, immunological derangement, microbiome dysbiosis especially Staphylococcus aureus predominance, and pruritus contribute to the development, progression, and chronicity of the disease.

Summary

AD is a complex and multifactorial disease. The skin barrier, dysbiosis of the skin microbiome, immune dysregulation, and severe itch all play a part in the pathogenesis of AD. Based on this progress, better targeted therapies are now emerging.

Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–22.PubMed

Wollina U. Atopic dermatitis and the metabolic syndrome. Clin Dermatol. 2018;36(1):62–6.PubMed

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78(1):54–61.PubMed

Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650–4.PubMed

Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–9.PubMed

Kawasaki H, Kubo A, Sasaki T, Amagai M. Loss-of-function mutations within the filaggrin gene and atopic dermatitis. Curr Probl Dermatol. 2011;41:35–46.PubMed

Venkataraman D, Soto-Ramírez N, Kurukulaaratchy RJ, Holloway JW, Karmaus W, Ewart SL, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014;134(4):876–882.e4.PubMedPubMedCentral

Fanton N, Santoro D, Cornegliani L, Marsella R. Increased filaggrin-metabolizing enzyme activity in atopic skin: a pilot study using a canine model of atopic dermatitis. Vet Dermatol. 2017;28(5):479–e111.PubMed

Matsui T, Miyamoto K, Kubo A, Kawasaki H, Ebihara T, Hata K, et al. SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol Med. 2011;3(6):320–33.PubMedPubMedCentral

10.

Hoste E, Kemperman P, Devos M, Denecker G, Kezic S, Yau N, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–41.PubMed

11.

Kawasaki H, Nagao K, Kubo A, Hata T, Shimizu A, Mizuno H, et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol. 2012;129:1538–1546.e1536.PubMed

12.

Jeong SK, Kim HJ, Youm JK, Ahn SK, Choi EH, Sohn MH, et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol. 2008;128:1930–9.PubMed

13.

Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134:792–9.PubMed

14.

Wang XW, Wang JJ, Gutowska-Owsiak D, Salimi M, Selvakumar TA, Gwela A, et al. Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function. Clin Exp Dermatol. 2017;42(6):622–31.PubMed

15.

Sekiya A, Kono M, Tsujiuchi H, Kobayashi T, Nomura T, Kitakawa M, et al. Compound heterozygotes for filaggrin gene mutations do not always show severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2017;31(1):158–62.PubMed

16.

Gruber R, Bonchen C, Rose K, Daubmann A, Volksdorf T, Wladykowski E, et al. Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. Am J Pathol. 2015;185:2777–89.PubMed

17.

De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773–86.PubMed

18.

Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One. 2016;11:e0161759.PubMedPubMedCentral

19.

Kim YE, Cho N, Cheon S, Kim KK. Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression. Biochem Biophys Res Commun. 2017 Nov 4;493(1):744–50.PubMed

20.

Li S, Villarreal M, Stewart S, Choi J, Ganguli-Indra G, Babineau DC, et al. Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitis. Br J Dermatol. 2017;177:e125–7.PubMedPubMedCentral

21.

Danso M, Boiten W, van Drongelen V, Gmelig Meijling K, Gooris G, El Ghalbzouri A, et al. Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci. 2017;88:57–66.PubMed

22.

Ito S, Ishikawa J, Naoe A, Yoshida H, Hachiya A, Fujimura T, et al. Ceramide synthase 4 is highly expressed in involved skin of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2017;31:135–41.PubMed

23.

Oh MJ, Nam JJ, Lee EO, Kim JW, Park CS. A synthetic C16 omega-hydroxyphytoceramide improves skin barrier functions from diversely perturbed epidermal conditions. Arch Dermatol Res. 2016;308:563–74.PubMed

24.

Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2018;178(1):e19–21.PubMed

25.

Nakatsuji T, Gallo RL. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol. 2012;132:887–95.PubMed

26.

Patra V, Mayer G, Gruber-Wackernagel A, Horn M, Lembo S, Wolf P. Unique profile of antimicrobial peptide expression in polymorphic light eruption lesions compared to healthy skin, atopic dermatitis, and psoriasis. Photodermatol Photoimmunol Photomed. 2018;34(2):137–44.PubMed

27.

Chieosilapatham P, Ogawa H, Niyonsaba F. Current insights into the role of human β-defensins in atopic dermatitis. Clin Exp Immunol. 2017 Nov;190(2):155–66.PubMedPubMedCentral

28.

Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2007;127:594–604.PubMed

29.

SPINK5 is associated with early-onset and CHI3L1 with late-onset atopic dermatitis. Int J Immunogenet. 2017;44(5):212–8.PubMed

30.

Zhao LP, Di Z, Zhang L, Wang L, Ma L, Lv Y, et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. J Eur Acad Dermatol Venereol. 2012;26:572–7.PubMed

31.

Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25:141–2.PubMed

32.

Hendricks AJ, Vaughn AR, Clark AK, Yosipovitch G, Shi VY. Sweat mechanisms and dysfunctions in atopic dermatitis. J Dermatol Sci. 2018;89(2):105–11.PubMed

33.

Wruhs M, Gleiß A, Steiner A, Sator P. Quantity and quality of sweating in atopic dermatitis. Arch Dermatol Res. 2017;309(10):787–93.PubMed

34.

Yamaga K, Murota H, Tamura A, Miyata H, Ohmi M, Kikuta J, et al. Claudin-3 loss causes leakage of sweat from the sweat gland to contribute to the pathogenesis of atopic dermatitis. J Invest Dermatol. 2018;138(6):1279–87.PubMed

35.

Rerknimitr P, Tanizaki H, Yamamoto Y, Amano W, Nakajima S, Nakashima C, et al. Decreased filaggrin level may lead to sweat duct obstruction in filaggrin mutant mice. J Invest Dermatol. 2017;137(1):248–51.PubMed

36.

Ignacio A, Breda CNS, Camara NOS. Innate lymphoid cells in tissue homeostasis and diseases. World J Hepatol. 2017;9(23):979–89.PubMedPubMedCentral

37.

Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–50.PubMedPubMedCentral

38.

Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367–70.PubMedPubMedCentral

39.

Kim BS, Wang K, Siracusa MC, Saenz SA, Brestoff JR, Monticelli LA, et al. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol. 2014;193(7):3717–25.PubMed

40.

Salimi M, Stöger L, Liu W, Go S, Pavord I, Klenerman P, et al. Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol. 2017;140(4):1090–100.

41.

Onoue A, Kabashima K, Kobayashi M, Mori T, Tokura Y. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp Dermatol. 2009;18:1036–43.PubMed

42.

Nakahigashi K, Kabashima K, Ikoma A, Verkman AS, Miyachi Y, Hara-Chikuma M. Upregulation of aquaporin-3 is involved in keratinocyte proliferation and epidermal hyperplasia. J Invest Dermatol. 2011;131:865–73.PubMed

43.

Totsuka A, Omori-Miyake M, Kawashima M, Yagi J, Tsunemi Y. Expression of keratin 1, keratin 10, desmoglein 1 and desmocollin 1 in the epidermis: possible downregulation by interleukin-4 and interleukin-13 in atopic dermatitis. Eur J Dermatol. 2017;27(3):247–53.PubMed

44.

Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis–part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127:1420–32.PubMed

45.

Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009;9:125–35.PubMedPubMedCentral

46.

Zeitvogel J, Jokmin N, Rieker S, Klug I, Brandenberger C, Werfel T. GATA3 regulates FLG and FLG2 expression in human primary keratinocytes. Sci Rep. 2017;7(1):11847.PubMedPubMedCentral

47.

Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159–70.PubMedPubMedCentral

48.

Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70:3–11.PubMed

49.

Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2012;129:879–86.PubMed

50.

Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–51.PubMed

51.

Narkajlma S, Kitoh A, Egawa G, et al. IL17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol. 2014;134:122–30.

52.

Glocova I, Brück J, Geisel J, Müller-Hermelink E, Widmaier K, Yazdi AS, et al. Induction of skin-pathogenic Th22 cells by epicutaneous allergen exposure. J Dermatol Sci. 2017;87(3):268–77.PubMed

53.

Floudas A, Saunders SP, Moran T, Schwartz C, Hams E, Fitzgerald DC, et al. IL-17 receptor a maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol. 2017;199(2):707–17.PubMed

54.

Orciani M, Campanati A, Caffarini M, Ganzetti G, Consales V, Lucarini G, et al. T helper (Th)1, Th17 and Th2 imbalance in mesenchymal stem cells of adult patients with atopic dermatitis: at the origin of the problem. Br J Dermatol. 2017;176(6):1569–76.PubMed

55.

Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017 Jul;35(3):317–26.PubMed

56.

Byrd AL, Deming C, Cassidy SKB, Harrison OJ, Ng WI, Conlan S, et al. Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med. 2017;9(397):eaal4651.PubMedPubMedCentral

57.

Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687–95.PubMed

58.

Nakatsuji T, Chen TH, Two AM, Chun KA, Narala S, Geha RS, et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Invest Dermatol. 2016;136(11):2192–200.PubMedPubMedCentral

59.

Nowicka D, Grywalska E. The role of immune defects and colonization of Staphylococcus aureus in the pathogenesis of atopic dermatitis. Anal Cell Pathol (Amst). 2018;2018:1956403.

60.

Corrigan RM, Miajlovic H, Foster TJ. Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiol. 2009;9:22PubMedPubMedCentral

61.

Mrabet-Dahbi S, Dalpke AH, Niebuhr M, Frey M, Draing C, Brand S, et al. The toll-like receptor 2 R753Q mutation modifies cytokine production and toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol. 2008;121:1013–9.PubMed

62.

Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel). 2013;5(6):1140–66.

63.

Williams MR, Nakatsuji T, Sanford JA, Vrbanac AF, Gallo RL. Staphylococcus aureus induces increased serine protease activity in keratinocytes. J Invest Dermatol. 2017;137(2):377–84.PubMed

64.

Volz T, Nega M, Buschmann J, Kaesler S, Guenova E, Peschel A, et al. Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J. 2010;24:4089–102.PubMed

65.

Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2006;281:2005–2011.

66.

Marrack P1, Blackman M, Kushnir E, Kappler J. The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med. 1990;171(2):455–64.PubMed

67.

Nakagawa S, Matsumoto M, Katayama Y, Oguma R, Wakabayashi S, Nygaard T, et al. Staphylococcus aureus virulent PSMα peptides induce keratinocyte alarmin release to orchestrate IL-17-dependent skin inflammation. Cell Host Microbe. 2017;22(5):667–677.e5.PubMedPubMedCentral

68.

Ohtsu H, Seike M. Histamine and histamine receptors in allergic dermatitis. Handb Exp Pharmacol. 2017;241:333–45.PubMed

69.

Seike M, Ikeda M, Kodama H, Terui T, Ohtsu H. Inhibition of scratching behaviour caused by contact dermatitis in histidine decarboxylase gene knockout mice. Exp Dermatol. 2005;14(3):169–75.PubMed

70.

Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007;119:176–83.PubMed

71.

Cataldi M, Borriello F, Granata F, Annunziato L, Marone G. Histamine receptors and antihistamines: from discovery to clinical applications. Chem Immunol Allergy. 2014;100:214–26.PubMed

72.

Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46(7):1727–50.PubMed

73.

Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147(1):71–9.PubMed

74.

Zhang D, Luo XR, Ye XQ, Dong XF. Determination of plasma and sputum substance P content in patients with chronic obstructive pulmonary disease or asthma. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(10):1314–5.PubMed

75.

Raap M, Rüdrich U, Ständer S, Gehring M, Kapp A, Raap U. Substance P activates human eosinophils. Exp Dermatol. 2015;24(7):557–9.PubMed

76.

Choi H, Kim DJ, Nam S, Lim S, Hwang JS, Park KS, et al. Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice. J Dermatol Sci. 2018;89(3):248–57.PubMed

77.

Akiyama T, Nguyen T, Curtis E, Nishida K, Devireddy J, Delahanty J, et al. A central role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240–6.PubMedPubMedCentral

78.

Lu J, Wu K, Zeng Q, Xiang Y, Gao L, Huang J. Serum interleukin-31 level and pruritus in atopic dermatitis: a meta-analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43(2):124–30.PubMed

79.

Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol. 2018;29(1):69–e28.PubMed

80.

Saleem MD, Oussedik E, D'Amber V, Feldman SR. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591–9.PubMed

81.

Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci. 2014;74(3):229–35.PubMed

82.

Andoh T, Li S, Uta D. Involvement of thromboxane A2 in interleukin-31-induced itch-associated response in mice. Pharmacol Rep. 2018 Apr;70(2):251–7.PubMed

83.

Hamann CR, Thyssen JP. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. J Am Acad Dermatol. 2018;78(3S1):S37–42.PubMed

84.

Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228.e13.PubMedPubMedCentral

85.

Afzal R, Shim WS. Glucosylsphingosine activates serotonin receptor 2a and 2b: implication of a novel itch signaling pathway. Biomol Ther (Seoul). 2017;25(5):497–503.

86.

Andersen HH, Elberling J, Sølvsten H, Yosipovitch G, Arendt-Nielsen L. Nonhistaminergic and mechanical itch sensitization in atopic dermatitis. Pain. 2017;158(9):1780–91.PubMed

Title: Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis
Authors: Houmin Li
Delphine J. Lee
Meiling Yuen
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Dermatology Reports / Issue 4/2018
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0238-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Wound Healing with Botanicals: a Review and Future Perspectives

Immune and Inflammatory Reponses to Staphylococcus aureus Skin Infections

Healing Chronic Wounds: Current Challenges and Potential Solutions

Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions

Skin Barrier Function and Atopic Dermatitis

Erythroderma and Figurate Erythemas